Daniel A.
- Country
- Spain
- Department
- Oncology
Research Overview
- Pumitamig plus Combination Therapy Versus Nivolumab plus Combination Therapy in Previously Untreated Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma
- Phase II Study of Total Neoadjuvant Durvalumab Plus FLOT Combination Therapy Followed by Postoperative Durvalumab in Resectable Gastroesophageal Adenocarcinoma
- Phase 1b/2 Study of S095029 and Pembrolizumab in MSI-H/dMMR Gastroesophageal Junction and Gastric Cancer
Data & Insights
Has run more than one trial at 45 of 136 partner sites.
Specializations
Gastrointestinal Oncology
The investigator specializes in treating various forms of gastrointestinal tract malignancies, with particular focus on gastric cancer and gastroesophageal junction adenocarcinoma.
- Advanced Gastric Cancer Management
- Metastatic GEJ Cancer Treatment
- Esophageal Cancer Therapy
Their expertise extends to both resectable and unresectable disease states.
Targeted Therapies
The investigator works extensively with targeted therapeutic approaches, particularly focusing on HER2-positive cancers and novel drug combinations.
- HER2-Targeted Treatments
- Immunotherapy Combinations
- Novel Agent Development
Their work encompasses both monotherapy and combination treatment strategies.
Immunotherapy Applications
The investigator focuses on immunotherapeutic approaches in gastrointestinal cancers, including work with PD-1 antibodies and novel immunotherapy combinations.
- Checkpoint Inhibitor Therapy
- Combination Immunotherapy
- Neoadjuvant Immunotherapy
Their research includes both early-stage and advanced disease settings.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.